Vasogen To Present at Needham & Company Biotechnology Conference

Toronto, Ontario - May 19, 2005

Vasogen Inc. (NASDAQ:VSGN; TSX:VAS), a leader in the research and development of immune modulation therapies targeting the chronic inflammation underlying cardiovascular and neurological disorders, today announced that its President and Chief Executive Officer, David Elsley, will present a Company overview at the Needham & Company Annual Biotechnology Conference at the New York Palace Hotel at 1:30 p.m. Eastern Time on Thursday, May 26, 2005 in New York City.

A live audio web cast of the presentation can be accessed through Vasogen’s Web site at: www.vasogen.com. An archived replay will be available following the presentation.

About Vasogen
Vasogen is focused on the research and commercial development of technologies targeting the chronic inflammation underlying cardiovascular and neurological disease. The Company’s lead product, the Celacade™ technology, is currently in two pivotal phase III clinical trials designed to support regulatory approval and marketing in North America and Europe. The 500-patient pivotal phase III SIMPADICO trial, which is fully enrolled at 50 centers in North America, is designed to further investigate the use of Celacade™ technology to improve intermittent claudication, a debilitating symptom associated with peripheral arterial disease. The 2,000-patient pivotal phase III ACCLAIM trial, designed to further investigate the use of Celacade™ technology to reduce the risk of death and hospitalization in patients with advanced chronic heart failure, is fully enrolled at 173 clinical centers in North America, Europe, and Israel. Vasogen is also developing a new class of drugs for the treatment of neuro-inflammatory disorders, which includes Alzheimer’s disease. VP025, the lead product candidate from this new class of drugs, is currently in phase I clinical development.

---